Tisotumab vedotin is designed to target tissue factor (TF) using our proprietary antibody–drug conjugate (ADC) technology. TF is highly expressed on many solid tumors, including ovarian, prostate, bladder, esophageal, endometrial, and lung tumors.1,2,3

Tisotumab vedotin is being developed in collaboration with Genmab.

Proposed mechanism of action

Seagen medication tisotumab vedotin

References

+
  1. Van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012;119(4):924-932.
  2. Cocco E, Varughese J, Buza N, et al. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. BMC cancer. 2011;11:263.
  3. Cocco E, Varughese J, Buza N, et al. Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. Clinical & experimental metastasis. 2011;28(7):689-700.